CN102302456B - Preparation method of tilmicosin phosphate microsphere specifically for use on animals - Google Patents
Preparation method of tilmicosin phosphate microsphere specifically for use on animals Download PDFInfo
- Publication number
- CN102302456B CN102302456B CN201110211098.1A CN201110211098A CN102302456B CN 102302456 B CN102302456 B CN 102302456B CN 201110211098 A CN201110211098 A CN 201110211098A CN 102302456 B CN102302456 B CN 102302456B
- Authority
- CN
- China
- Prior art keywords
- phosphoric acid
- preparation
- mixture
- microspheres
- tilmicosin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of preparation of animal drugs, and particularly discloses a preparation method of a tilmicosin phosphate microsphere specifically for use on animals. The preparation method comprises the steps of: solving acrylic resin into absolute ethyl alcohol to make up a solution with a certain concentration; adding the soybean oil solution of the tilmicosin phosphate to obtain uniformly mixed phase; slowly dropping the mixed phase into liquid paraffin comprising Span 80 (SP80) and silicon dioxide; bathing in water and stirring at 40 DEG C to fully volatilize the absolute ethyl alcohol so as to form cured microsphere; centrifuging; removing the liquid paraffin on the surface of the microsphere through washing for many times by use of few petroleum ether, and drying at 40 DEG C to obtain the tilmicosin phosphate microsphere specifically for use on animals. The preparation method of tilmicosin phosphate microsphere specifically for use on animals has the advantages of simple operation in preparation technology and low requirement on preparation equipment and conditions. The prepared microsphere better solves the problem of drug palatability.
Description
Technical field
The invention belongs to the preparing technical field of animal drug, be specifically related to a kind of preparation method of Macrolide antimicrobial drug phosphoric acid tilmicosin microspheres of animal specific.
Background technology
Tilmicosin (tilmicosin) is a kind ofly to take tylosin as the special-purpose antibiotic of the semisynthetic poultry of precursor, by Britain Elanco company, the eighties in 20th century, developed, there is very strong antibacterial activity, has a broad antifungal spectrum, drug resistance is low, and all gram positive bacterias and part gram negative bacteria, spirillum, Mycoplasma etc. are all had to inhibitory action.Veterinary clinic is commonly used its phosphate, but generally poor because of the palatability of existing phosphoric acid tilmicosin preparation, affects searching for food of animal, thereby has reduced the curative effect of medicine to disease.
Summary of the invention
For the deficiencies in the prior art, the object of the present invention is to provide a kind of preparation method of animal specific phosphoric acid tilmicosin microspheres, after adopting specific coating coated the fallow phosphoric acid tilmicosin crude drug to light red brown particle shape, obtain the white phosphoric acid tilmicosin microspheres that drug loading is moderate, envelop rate is high, solved the poor problem of this medicine palatability, to meet better need of production.
To achieve these goals, the preparation method of a kind of animal specific phosphoric acid of technical scheme of the present invention tilmicosin microspheres, its step is as follows:
1. acrylic resin is dissolved in dehydrated alcohol, is mixed with the ethanol solution that concentration is the acrylic resin of 5-15wt%, be called solution A;
Described acrylic resin is German rom (Rohm) acrylic resin (especially strange) RSPO;
2. phosphoric acid tilmicosin crude drug and soybean oil are mixed according to weight ratio 1:1.25-1:6.5, stir and make both mix homogeneously, obtain mixture B;
3. solution A is joined in mixture B, ultrasonic 1min fully mixes it, obtains mixture C;
Wherein the weight ratio of the phosphoric acid tilmicosin crude drug in mixture B and the acrylic resin in solution A is 1:2.12-1:3.52;
4. Arlacel-80 (SP-80), powder silicon dioxide and liquid paraffin are mixed and be placed in 40 ℃ of water-baths, under the speed of 800-1000r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 1-3h, make absolute ethanol volatilizes complete, obtain mixture D;
Wherein in Arlacel-80, powder silicon dioxide, liquid paraffin and mixture C, the ratio of institute's phosphoric acid tilmicosin crude drug is: (0.45-0.75g): (0.3-0.5g): (30-50mL): (0.25-0.5g);
5. mixture D petroleum ether 3 times, to wash away liquid paraffin, then carry out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres of the present invention.
It is raw material that the fallow phosphoric acid tilmicosin crude drug to light red brown particle shape is take in the present invention, acrylic resin is coating, water soluble drug powder packets is entrained in the Semen sojae atricolor oil phase of sealing coat, by interface molecular force, wrap up and the encapsulation for the second time of hydrophobic polymer solution subsequently.Prepared microsphere is greatly improved the palatability of medicine, and the envelop rate of medicine reaches 74.57%～99.82%.
Advantage of the present invention and beneficial effect are as follows:
1, the present invention adopts the coating acrylic resin that people's medicine is conventional to be coated with the poor phosphoric acid tilmicosin crude drug of palatability, and the envelop rate of medicine is significantly improved compared with additive method;
2, in the present invention, selected preparation technology is simple, and good stability, has good commercial application prospect;
3, the prepared phosphoric acid tilmicosin microspheres of the inventive method has solved the poor problem of the caused palatability of crude drug Direct-fed well, for good basis has been established in the clinical practice of medicine.
Accompanying drawing explanation
The drug dissolution curve chart of Fig. 1 embodiment 1;
The drug dissolution curve chart of Fig. 2 embodiment 2;
The drug dissolution curve chart of Fig. 3 embodiment 3;
The drug dissolution curve chart of Fig. 4 embodiment 4.
The specific embodiment
Below in conjunction with specific embodiment, the inventive method is further elaborated.
Embodiment 1
A preparation method for animal specific phosphoric acid tilmicosin microspheres, its step is as follows:
(1) take acrylic resin RSPO1.11g, be dissolved in the dehydrated alcohol of 10mL, obtain solution A;
(2) take 0.5g phosphoric acid tilmicosin crude drug, join in 1.25g soybean oil, stir, obtain mixture B;
(3) solution A is joined in mixture B, ultrasonic 1min fully mixes it, obtains mixture C;
(4) 0.75g SP-80,0.5g silicon dioxide and 50mL liquid paraffin are mixed and be placed in 40 ℃ of water-baths, under the speed of 900r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 1.0h, make absolute ethanol volatilizes complete, obtain mixture D;
(5) petroleum ether 3 times for mixture D is used petroleum ether 20mL at every turn, vibrates after centrifugal and discards solution, to wash away liquid paraffin, then carries out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres of the present invention.
The physicochemical property of the phosphoric acid tilmicosin microspheres of gained is stable, and the result that records drug loading and envelop rate by high performance liquid chromatography is respectively 24.56% and 74.57%.The microsphere sample that this example is made is distributed into three batches, deposit respectively to 4 ℃ of refrigerators, room temperature and 40 ℃ of baking ovens and investigate, before mode of appearance, particle diameter and the distribution thereof of discovery microsphere, drug loading, tablets in vitro percentage rate and investigation, all without significant change, polymeric microspheres stabilize is good.
A preparation method for animal specific phosphoric acid tilmicosin microspheres, its step is as follows:
(1) take acrylic resin RSPO0.53g, be dissolved in the dehydrated alcohol of 10mL, obtain solution A;
(2) take 0.25g phosphoric acid tilmicosin crude drug, join in 0.625g soybean oil, stir, obtain mixture B;
(3) solution A is joined in mixture B, ultrasonic 1min fully mixes it, obtains mixture C;
(4) 0.45g SP-80,0.5g silicon dioxide and 50mL liquid paraffin are mixed and be placed in 40 ℃ of water-baths, under the speed of 900r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 1.5h, make absolute ethanol volatilizes complete, obtain mixture D;
(5) petroleum ether 3 times for mixture D is used petroleum ether 20mL at every turn, vibrates after centrifugal and discards solution, to wash away liquid paraffin, then carries out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres of the present invention.
The physicochemical property of the phosphoric acid tilmicosin microspheres of gained is stable, and the result that records drug loading and envelop rate by high performance liquid chromatography is respectively 26.45% and 99.82%.The microsphere sample that this example is made is distributed into three batches, deposit respectively to 4 ℃ of refrigerators, room temperature and 40 ℃ of baking ovens and investigate, before mode of appearance, particle diameter and the distribution thereof of discovery microsphere, drug loading, tablets in vitro percentage rate and investigation, all without significant change, polymeric microspheres stabilize is good.
Embodiment 3
A preparation method for animal specific phosphoric acid tilmicosin microspheres, its step is as follows:
(1) take acrylic resin RSPO1.11g, be dissolved in the dehydrated alcohol of 10mL, obtain solution A;
(2) take 0.375g phosphoric acid tilmicosin crude drug, join in 0.625g soybean oil, stir, obtain mixture B;
(3) solution A is joined in mixture B, ultrasonic 1min fully mixes it, obtains mixture C;
(4) 0.6g SP-80,0.4g silicon dioxide and the mixing of 40mL liquid paraffin are placed in 40 ℃ of water-baths, under the speed of 900r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 2.0h, make absolute ethanol volatilizes complete, obtain mixture D;
(5) petroleum ether 3 times for mixture D is used petroleum ether 20mL at every turn, vibrates after centrifugal and discards solution, to wash away liquid paraffin, then carries out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres of the present invention.
The physicochemical property of the phosphoric acid tilmicosin microspheres of gained is stable, and the result that records drug loading and envelop rate by high performance liquid chromatography is respectively 25.39% and 97.83%.The microsphere sample that this example is made is distributed into three batches, deposit respectively to 4 ℃ of refrigerators, room temperature and 40 ℃ of baking ovens and investigate, before mode of appearance, particle diameter and the distribution thereof of discovery microsphere, drug loading, tablets in vitro percentage rate and investigation, all without significant change, polymeric microspheres stabilize is good.
A preparation method for animal specific phosphoric acid tilmicosin microspheres, its step is as follows:
(1) take acrylic resin RSPO1.76g, be dissolved in the dehydrated alcohol of 10mL, obtain solution A;
(2) take 0.5g phosphoric acid tilmicosin crude drug, join in 1.625g soybean oil, stir, obtain mixture B;
(3) solution A is joined in mixture B, ultrasonic 1min fully mixes it, obtains mixture C;
(4) 0.75g SP-80,0.5g silicon dioxide and 50mL liquid paraffin are mixed and be placed in 40 ℃ of water-baths, under the speed of 1000r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 1.5h, make absolute ethanol volatilizes complete, obtain mixture D;
(5) petroleum ether 3 times for mixture D is used petroleum ether 20mL at every turn, vibrates after centrifugal and discards solution, to wash away liquid paraffin, then carries out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres of the present invention.
The physicochemical property of the phosphoric acid tilmicosin microspheres of gained is stable, and the result that records drug loading and envelop rate by high performance liquid chromatography is respectively 26.88% and 96.72%.The microsphere sample that this example is made is distributed into three batches, deposit respectively to 4 ℃ of refrigerators, room temperature and 40 ℃ of baking ovens and investigate, before mode of appearance, particle diameter and the distribution thereof of discovery microsphere, drug loading, tablets in vitro percentage rate and investigation, all without significant change, polymeric microspheres stabilize is good.
Phosphoric acid tilmicosin microspheres Dissolution Rate Testing
One, experiment material
1. main agents and medicine
Phosphoric acid tilmicosin microspheres (the prepared product of embodiments of the invention); The equal Pass Test requirement of other reagent.
2. key instrument equipment
RC-6D type drug dissolution tester, Tianjin Guoming Medicine Equipment Co., Ltd..
Two, experimental technique
Take phosphoric acid tilmicosin microspheres 0.1g, with reference to Chinese < < Chinese veterinary pharmacopoeia > > (version in 2010) First dissolution method first method, take 900mL0.02%Tween-20(g/mL) aqueous solution is release medium, rotating speed is 75rpm, temperature is 37 ± 0.5 ℃, respectively at 5min, 10min, 15min, 30min, 45min, 1h, 1.5h, 2h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, when 11h and 12h, sample 5mL(and supplement the synthermal fresh dissolution medium of equal-volume simultaneously), measure in accordance with the law, calculate its dissolution.
Three, experimental result
Carry out as stated above dissolution determination, the medicine microspheres release curve chart of embodiment 1-4 is shown in that Fig. 1 is to Fig. 4.As we know from the figure, the rate of release of the microsphere Chinese medicine of embodiment 1 is fast compared with other 3 embodiment's, and short compared with other embodiment of the interval that discharges of sustained drug.The release profiles of embodiment 2,3,4 microsphere Chinese medicines is close.In microsphere, phosphoric acid tilmicosin is the trend that continues slow release, and the release initial stage of phosphoric acid tilmicosin microspheres is quick release, and in this stage, the medicine that is present in microsphere surface discharges quickly; Later stage is slow release, and the medicine being present in acrylic resin microsphere hole discharges gradually.
Phosphoric acid tilmicosin microspheres palatability testing
One, experiment material
1. main agents and medicine
Phosphoric acid tilmicosin microspheres (the prepared product of embodiments of the invention), Zhi Lejing (Wuhan Hvsen Biotechnology Co., Ltd.'s product).
2. laboratory animal
Landrace, body weight 25-30kg, totally 36, to raise in cages, free choice feeding drinking-water, feeds not containing the adequate diet of antibacterials, raises 5d before test.
Two, experimental technique
1. animal grouping
36 pigs are divided into 6 groups at random, every group of 6 repetitions.
I group is fed and is not contained the complete feedstuff (matched group) of antibacterials;
II group is fed and is added the complete feedstuff of Zhi Lejing;
III group is fed and is added the complete feedstuff of the prepared phosphoric acid tilmicosin microspheres of embodiment 1;
IV group is fed and is added the complete feedstuff of the prepared phosphoric acid tilmicosin microspheres of embodiment 2;
V group is fed and is added the complete feedstuff of the prepared phosphoric acid tilmicosin microspheres of embodiment 3;
VI group is fed and is added the complete feedstuff of the prepared phosphoric acid tilmicosin microspheres of embodiment 4.
2. administration
Control animals is pressed the administration of Zhi Lejing operation instructions, in other test group, first the medicine in microsphere and crude drug is carried out to content conversion, guarantees that the phosphoric acid tilmicosin content that each test group feeds with II group is identical.15d continuously feeds.
3. evaluation index
With daily ingestion amount, daily gain and three indexs of feedstuff-meat ratio, evaluate the palatability problem of coated rear medicine (phosphoric acid tilmicosin microspheres).
Three, experimental result
Daily ingestion amount, daily gain and the feedstuff-meat ratio of feeding after the product of each embodiment the results are shown in Table 1-4.
Daily ingestion amount, daily gain and the feedstuff-meat ratio of 1 three groups of table 1 embodiment
The relative deviation that adds the experimental group of phosphoric acid tilmicosin microspheres and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-34.27% ,-43.81% and 17.20%; The relative deviation that adds the experimental group of phosphoric acid tilmicosin and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-44.87% ,-53.47% and 19.0%; The experimental group that adds phosphoric acid tilmicosin is respectively-24.26% ,-24.46% and 0.31% with the relative deviation of daily ingestion amount, daily gain and the feedstuff-meat ratio of the experimental group of interpolation phosphoric acid tilmicosin microspheres.
Daily ingestion amount, daily gain and the feedstuff-meat ratio of 2 three groups of table 2 embodiment
The relative deviation that adds the experimental group of phosphoric acid tilmicosin microspheres and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-5.35% ,-5.44% and 0.36%; The relative deviation that adds the experimental group of phosphoric acid tilmicosin and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-44.87% ,-53.47% and 19.0%; The experimental group that adds phosphoric acid tilmicosin is respectively-41.76% ,-50.79% and 18.57% with the relative deviation of daily ingestion amount, daily gain and the feedstuff-meat ratio of the experimental group of interpolation phosphoric acid tilmicosin microspheres.
Daily ingestion amount, daily gain and the feedstuff-meat ratio of 3 three groups of table 3 embodiment
The relative deviation that adds the experimental group of phosphoric acid tilmicosin microspheres and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-7.73% ,-4.22% and 1.0%; The relative deviation that adds the experimental group of phosphoric acid tilmicosin and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-50.22% ,-57.55% and 17.56%; The experimental group that adds phosphoric acid tilmicosin is respectively-49.68% ,-55.68% and 13.49% with the relative deviation of daily ingestion amount, daily gain and the feedstuff-meat ratio of the experimental group of interpolation phosphoric acid tilmicosin microspheres.
Daily ingestion amount, daily gain and the feedstuff-meat ratio of 4 three groups of table 4 embodiment
The relative deviation that adds the experimental group of phosphoric acid tilmicosin microspheres and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-7.73% ,-8.03% and 0.72%; The relative deviation that adds the experimental group of phosphoric acid tilmicosin and daily ingestion amount, daily gain and the feedstuff-meat ratio of matched group is respectively-50.22% ,-57.55% and 17.56%; The experimental group that adds phosphoric acid tilmicosin is respectively-46.05% ,-53.85% and 16.73% with the relative deviation of daily ingestion amount, daily gain and the feedstuff-meat ratio of the experimental group of interpolation phosphoric acid tilmicosin microspheres.
Result shows: the phosphoric acid tilmicosin microspheres after coated in embodiment 1-4, has had good improvement compared with Direct-fed phosphoric acid tilmicosin crude drug to the palatability of animal.
Claims (1)
1. a preparation method for animal specific phosphoric acid tilmicosin microspheres, its step is as follows:
(1) take especially strange RSPO 0.53 g of acrylic resin, be dissolved in the dehydrated alcohol of 10 mL, obtain solution A;
(2) take 0.25 g phosphoric acid tilmicosin crude drug, join in 0.625 g soybean oil, stir, obtain mixture B;
(3) solution A is joined in mixture B, ultrasonic 1 min fully mixes it, obtains mixture C;
(4) 0.45g Arlacel-80,0.5g silicon dioxide and 50 mL liquid paraffin are mixed and are placed in 40 ℃ of water-baths, under the speed of 900r/min stirs, drip mixture C, drip and finish rear continuation at 40 ℃ of stirred in water bath 1.5 h, make absolute ethanol volatilizes complete, obtain mixture D;
(5) petroleum ether 3 times for mixture D is used petroleum ether 20mL at every turn, vibrates after centrifugal and discards solution, to wash away liquid paraffin, then carries out vacuum filtration, and gained solid is dried at 40 ℃, obtains phosphoric acid tilmicosin microspheres.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110211098.1A CN102302456B (en) | 2011-07-26 | 2011-07-26 | Preparation method of tilmicosin phosphate microsphere specifically for use on animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110211098.1A CN102302456B (en) | 2011-07-26 | 2011-07-26 | Preparation method of tilmicosin phosphate microsphere specifically for use on animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102302456A CN102302456A (en) | 2012-01-04 |
| CN102302456B true CN102302456B (en) | 2014-03-12 |
Family
ID=45376446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110211098.1A Active CN102302456B (en) | 2011-07-26 | 2011-07-26 | Preparation method of tilmicosin phosphate microsphere specifically for use on animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102302456B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002529400A (en) * | 1998-11-10 | 2002-09-10 | アイデックス ラボラトリーズ インコーポレイテッド | Phospholipid-coated microcrystals for sustained release of pharmacologically active compounds and their production and use |
| CN101450069A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating poultry respiratory infection |
| CN101590009A (en) * | 2008-05-30 | 2009-12-02 | 北京大北农动物保健科技有限责任公司 | New formulation of a kind of veterinary tilmicosin and salt thereof and preparation method thereof |
| CN101810582A (en) * | 2009-11-10 | 2010-08-25 | 郑州后羿制药有限公司 | Method for preparing veterinary tilmicosin microspheres |
| CN102000105A (en) * | 2010-10-11 | 2011-04-06 | 西北农林科技大学 | Compound timicosin oral liquid and preparation method thereof |
-
2011
- 2011-07-26 CN CN201110211098.1A patent/CN102302456B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002529400A (en) * | 1998-11-10 | 2002-09-10 | アイデックス ラボラトリーズ インコーポレイテッド | Phospholipid-coated microcrystals for sustained release of pharmacologically active compounds and their production and use |
| CN101450069A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating poultry respiratory infection |
| CN101590009A (en) * | 2008-05-30 | 2009-12-02 | 北京大北农动物保健科技有限责任公司 | New formulation of a kind of veterinary tilmicosin and salt thereof and preparation method thereof |
| CN101810582A (en) * | 2009-11-10 | 2010-08-25 | 郑州后羿制药有限公司 | Method for preparing veterinary tilmicosin microspheres |
| CN102000105A (en) * | 2010-10-11 | 2011-04-06 | 西北农林科技大学 | Compound timicosin oral liquid and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 替米考星淀粉微球的制备及缓释性能的研究;李仲谨等,1;《中国畜牧兽医》(第11期);230-234 * |
| 李仲谨等,1.替米考星淀粉微球的制备及缓释性能的研究.《中国畜牧兽医》.(第11期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102302456A (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106390136A (en) | Water-soluble florfenicol clathrate with high bioavailability and preparation method of water-soluble florfenicol clathrate | |
| CN105125524B (en) | Tilmicosin enteric-coated micro-pill and preparation method thereof | |
| CN103083281A (en) | Enteric-coated tilmicosin slow-release micro-capsule preparation and preparation method thereof | |
| CN103751103A (en) | Long-acting cefquinome sulfate injection and preparation method thereof | |
| CN103301144A (en) | Antibiotic premixing agent for inhibiting porcine reproductive and respiratory syndrome virus for livestock and preparation method thereof | |
| CN108815123A (en) | A kind of curcumin solid dispersion and its preparation method and application | |
| US20230087524A1 (en) | Microcapsule powder stable in gastric acid, method for preparing same, and use thereof | |
| CN111643456A (en) | Preparation method and application of florfenicol solid dispersion with high dissolution rate | |
| CN110075082B (en) | Enrofloxacin quick-release pellet and preparation method thereof | |
| CN102302456B (en) | Preparation method of tilmicosin phosphate microsphere specifically for use on animals | |
| CN109893513B (en) | Composite haematococcus pluvialis astaxanthin self-emulsifying soft capsule and preparation method and application thereof | |
| CN104814931A (en) | Olaquindox slow release particle and preparing method and application thereof | |
| CN102266347A (en) | Phospholipid/cholate composite micelles of glycyrrhizic acid and preparation method and preparation thereof | |
| CN104906179A (en) | Origanum oil suspension and preparation method thereof | |
| CN116036020B (en) | Florfenicol powder with high bioavailability and preparation method thereof | |
| CN101982173A (en) | Danofloxacin mesylate-amoxicillin suspension injection applicable to livestock and poultry as well as preparation and application thereof | |
| CN103622987A (en) | Veterinary long-acting compound lincomycin hydrochloride injection and preparation method thereof | |
| CN101766569B (en) | Long-acting antimicrobial medical oil emulsion and preparation method thereof | |
| CN102872002B (en) | Hydroxysafflor yellow A oil solution and preparation method and application thereof | |
| CN103239497B (en) | Enrofloxacin clathrate compound and preparation method thereof | |
| CN105267977A (en) | Dissolvable doxycycline powder and preparation method thereof | |
| CN104586757A (en) | Veterinary enrofloxacin injection and preparation method thereof | |
| CN101732315A (en) | Method for preparing enrofloxacin microcapsules | |
| CN113616623A (en) | Microcapsule oral medicine based on yeast delivery carrier and preparation method and application thereof | |
| CN102920763B (en) | Lutein ester enteric microcapsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 430042 Hubei province Dongxihu District of Wuhan City Road No. 208 Zhang Patentee after: Wuhan Sheng Sheng biological Polytron Technologies Inc Address before: 430042 Hubei province Dongxihu District of Wuhan City Road No. 208 Zhang Patentee before: Wuhan Hvsen Biotechnology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190430 Address after: 410011 No. 107 Kangtian Road, Liuyang Economic and Technological Development Zone, Changsha City, Hunan Province Patentee after: Changsha SPN Animal Pharmaceutical Co., Ltd. Address before: 430042 No. 208 Zhangbai Road, Dongxihu District, Wuhan City, Hubei Province Patentee before: Wuhan Sheng Sheng biological Polytron Technologies Inc |